

Moderna's CFO on How to Allocate Capital in Big Pharma
4 snips Mar 11, 2024
Jamey Mock, Chief Financial Officer of Moderna, shares his insights on capital allocation in the unpredictable world of pharmaceuticals. He discusses how the lengthy drug development process complicates investment decisions. The impact of government funding during the pandemic on corporate strategy is explored, as is the importance of balancing long-term innovation with immediate market demands. Jamey also touches on the financial dynamics following Moderna's successful COVID vaccine, highlighting their considerable cash reserves and future investment plans.
AI Snips
Chapters
Transcript
Episode notes
Moderna's Rise
- Tracey Alloway mentions Moderna's relative obscurity pre-pandemic.
- She notes its rapid rise to household name status during the pandemic.
Moderna's mRNA Platform
- Moderna's platform revolves around mRNA, which produces proteins in the body.
- These proteins can combat infectious diseases or act as therapies in areas like oncology and rare diseases.
Managing Risk in Drug Development
- Assess the risks and capabilities of each drug candidate throughout the development process.
- Start with small patient groups in phase one trials and gradually expand in later phases.